Chemical-structure (Chemical Structure)
Sumatriptan Succinate Tablet, Film Coated
Product Images NDC 71205-251
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Sumatriptan Succinate (NDC 71205-251). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
71205-251-09 (Sumatriptan Carton 50mg)
This is a medication package for Sumatriptan Succinate 50mg tablets by Proficient Rx LP. The tablets are white, triangular-shaped, film-coated, and each contain sumatriptan succinate USP equivalent to 50mg of sumatriptan. The tablets are marked with "S" on one side and "50" on the other. The package comes with 9 tablets with a lot number and expiration date. The medication should only be used with a prescription and must be kept out of children's reach at a temperature between 20°C and 25°C (68°F and 77°F).*
Sumatriptan-figure-1 (Sumatriptan Figure 1)
This is a figure showing the estimated probability of responding to oral sumatriptan within 4 hours of treatment for a headache. The data is based on pooled information from three clinical controlled trials that show the efficacy of the medication. The probabilities are shown on a graph over time, with different dosages of sumatriptan displayed. The graph is a Kaplan-Meier plot that is censored at 240 minutes for patients who did not achieve a response or had to take rescue medication.*
Sumatriptan-figure-2 (Sumatriptan Figure 2)
This is a figure and a table showing the estimated probability of patients taking a second dose of Sumatriptan Succinate Tablets or other medication to treat migraine over the 24 hours following the initial dose of study treatment in pooled trials 1, 2, and 3. The Kaplan-Meier plot is based on data obtained in the 3 clinical controlled trials which provide evidence of efficacy with patients not using additional treatments censored to 24 hours. The plot also includes patients who had no response to the initial dose. No remedication was allowed within 2 hours postdose.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
